Centessa to present data from third year of Phase 2a study of SerpinPC

Centessa Pharmaceuticals announced that data from an additional 52-weeks of continuous treatment from the third year of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia, will be presented during an oral presentation at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders in Frankfurt, Germany, today, February 9, 2024. “EAHAD provides an exciting opportunity to highlight the therapeutic potential of SerpinPC,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. “The compelling data from the ongoing Phase 2a study further demonstrate the potential for SerpinPC to be a convenient subcutaneous treatment with a differentiated safety profile for people living with hemophilia. These data also reinforce our confidence in SerpinPC’s novel mechanism of action as we continue to advance the registrational studies with the goal of bringing a new therapy option to patients and physicians.”